ICP
IBB icon

Interchange Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Interchange Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,256
Closed -$381K – 388
2025
Q4 		$381K Buy
+2,256
New +$366K 0.07% 246

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Interchange Capital Partners's IBB Position: Q1 2026 in Review

Interchange Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 2,256 shares — an estimated $381K sold.

Interchange Capital Partners first reported a position in IBB in Q4 2025 and held it in 1 quarter. The position peaked at $381K in Q4 2025. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Interchange Capital Partners reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
  • Interchange Capital Partners sold 2,256 iShares Biotechnology ETF shares in Q1 2026, an estimated $381K.
  • Interchange Capital Partners first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 1 quarter.
  • Interchange Capital Partners's iShares Biotechnology ETF position peaked at $381K in Q4 2025.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.